Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants

NCT02391415 is registered in ClinicalTrials.gov with Serum Institute of India Pvt. Ltd. as lead sponsor.

NCT NCT02391415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02391415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants
Lead sponsor
Serum Institute of India Pvt. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
November 30, 2017
Enrollment
416 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis